• Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

    ソース: Nasdaq GlobeNewswire / 06 11 2024 16:05:00   America/New_York

    FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November.

    UBS Global Healthcare Conference
    Format: Fireside Chat         
    Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PT
    Location: Terranea Resort, Rancho Palos Verdes

    Jefferies London Healthcare Conference
    Format: Fireside Chat
    Date and Time: Tuesday, November 19, 2024 at 5:00 p.m. GMT
    Location: Waldorf Hilton, London

    Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

    About Terns Pharmaceuticals
    Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.

    Contacts for Terns

    Investors
    Justin Ng
    investors@ternspharma.com

    Media
    Jenna Urban
    Berry & Company Public Relations
    media@ternspharma.com


    Primary Logo

シェアする